4N9G

Crystal Structure of a Computationally Designed RSV-Presenting Epitope Scaffold And Its Elicited Antibody 17HD9


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.5 Å
  • R-Value Free: 0.295 
  • R-Value Work: 0.263 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Proof of principle for epitope-focused vaccine design.

Correia, B.E.Bates, J.T.Loomis, R.J.Baneyx, G.Carrico, C.Jardine, J.G.Rupert, P.Correnti, C.Kalyuzhniy, O.Vittal, V.Connell, M.J.Stevens, E.Schroeter, A.Chen, M.Macpherson, S.Serra, A.M.Adachi, Y.Holmes, M.A.Li, Y.Klevit, R.E.Graham, B.S.Wyatt, R.T.Baker, D.Strong, R.K.Crowe, J.E.Johnson, P.R.Schief, W.R.

(2014) Nature 507: 201-206

  • DOI: 10.1038/nature12966
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies against vulnerable epitopes. Several major pathogens have resisted traditional vaccine development, although vulnerable epitopes targeted by neutralizing antib ...

    Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies against vulnerable epitopes. Several major pathogens have resisted traditional vaccine development, although vulnerable epitopes targeted by neutralizing antibodies have been identified for several such cases. Hence, new vaccine design methods to induce epitope-specific neutralizing antibodies are needed. Here we show, with a neutralization epitope from respiratory syncytial virus, that computational protein design can generate small, thermally and conformationally stable protein scaffolds that accurately mimic the viral epitope structure and induce potent neutralizing antibodies. These scaffolds represent promising leads for the research and development of a human respiratory syncytial virus vaccine needed to protect infants, young children and the elderly. More generally, the results provide proof of principle for epitope-focused and scaffold-based vaccine design, and encourage the evaluation and further development of these strategies for a variety of other vaccine targets, including antigenically highly variable pathogens such as human immunodeficiency virus and influenza.


    Organizational Affiliation

    1] Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA [2] PhD Program in Computational Biology, Instituto Gulbenkian Ciência and Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras 2780-157, Portugal [3] Department of Chemical Physiology, The Scripps Research Institute, La Jolla, California 92037, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Antibody 17HD9, Heavy Chain
A, E, H, M
230N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Antibody 17HD9, Light Chain
B, F, L, N
215N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
Epitope Scaffold rsv_1isea_FFL_001_C
C, D, Y, Z
123N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.5 Å
  • R-Value Free: 0.295 
  • R-Value Work: 0.263 
  • Space Group: P 1
Unit Cell:
Length (Å)Angle (°)
a = 64.213α = 89.99
b = 89.266β = 102.73
c = 104.304γ = 89.91
Software Package:
Software NamePurpose
REFMACrefinement
d*TREKdata reduction
d*TREKdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2014-02-12
    Type: Initial release